Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on TENX. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research note on Monday. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Stock Up 0.8 %

Shares of TENX opened at $6.41 on Thursday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The firm’s 50 day moving average price is $6.44 and its 200 day moving average price is $5.23.

Institutional Trading of Tenax Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in Tenax Therapeutics during the 4th quarter worth about $84,000. Millennium Management LLC bought a new stake in Tenax Therapeutics during the 4th quarter worth about $166,000. Janus Henderson Group PLC acquired a new position in shares of Tenax Therapeutics during the 4th quarter worth about $1,026,000. Geode Capital Management LLC grew its position in shares of Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 5,964 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth about $101,000. 1.67% of the stock is owned by institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.